Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Eliem Therapeutics Inc (ELYM)

Eliem Therapeutics Inc (ELYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder Globe Newswire - Mon Jul 18, 2022

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022 Globe Newswire - Thu Jul 7, 2022

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP) Globe Newswire - Mon Jun 27, 2022

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Reports First Quarter Financial and Business Highlights Globe Newswire - Mon May 16, 2022

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics to Present at Stifel’s 2022 CNS Days Globe Newswire - Mon Mar 21, 2022

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights Globe Newswire - Mon Mar 7, 2022

 Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 ...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference Globe Newswire - Fri Feb 11, 2022

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022 Globe Newswire - Mon Feb 7, 2022

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Globe Newswire - Mon Nov 8, 2021

Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress...

ELYM : 5.11 (-0.97%)
Eliem Therapeutics Reports Second Quarter Financial Results Globe NewsWire - Mon Sep 13, 2021

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months

ELYM : 5.11 (-0.97%)

Barchart Exclusives

Use Stochastics to Extract a 23% Yield from AMD Stock Options This Week Barchart - 42 minutes ago
Through a risky but enticing iron condor, investors can potentially grab some income in just one week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot